Influence of treatment modalities on survival and progression free survival in primary spinal cord glioblastoma: a systematic review and individual participant data meta-analysis
European Spine Journal · 2025
DOI: 10.1007/s00586-025-09516-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Spine Journal, 2025. Verfasst von Pedro Lucas Negromonte Guerra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hospital da Restauração, Recife, Brazil. pedronegromontee@gmail.com. Hauptthemen laut MEDLINE: Glioblastoma, Spinal Cord Neoplasms. Die Arbeit nennt 126 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system, primarily affecting the brain. It infrequently occurs in the spinal cord, accounting for approximately 1.5% of all spinal cord tumors. Primary spinal cord GBM (sGBM) is associated with a poor prognosis, with a median overall survival (OS) of 12-15 months and a median progression-free survival (PFS) of 11.5 months. This study performed a systematic review and a individual participant data meta-analysis to evaluate the impact of various therapeutic strategies on OS and PFS in patients with sGBM. METHODS: Following PRISMA guidelines, data from 278 patients extracted from 116 studies were analyzed. The literature search was conducted in August 2025 using the PubMed and Embase databases. Statistical analyses included Kaplan-Meier survival curves, the log-rank test, and univariate and multivariate Cox regression models. RESULTS: The average age was 31 years, with a predominance of males (57.5%). Most patients underwent STR (63.6%) and received adjuvant treatment (84.6%). Mean OS was 16.1 months, while mean PFS was 11.6 months. Chemotherapy (CT) and Radiotherapy (RT) were associated with improved prognosis. Moreover, patients who underwent gross total resection (GTR) showed a lower risk of mortality compared with those who underwent Bx. CONCLUSION: Chemotherapy, radiotherapy, and gross total resection demonstrated significant benefits for both OS and PFS. These findings underscore the relevance of adjuvant therapies and surgical extent in the management of primary spinal GBM. Future studies should address the impact of tumor genetic and molecular profiles on survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital da Restauração, Recife, Brazil. pedronegromontee@gmail.com.
- Hospital da Restauração, Recife, Brazil.
- Saitama Red Cross Hospital, Saitama, Japan.
- Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.
Zitieren
APA
Guerra, P. L. N., Silva, I. C. S., Lima, D., Souza, M. R., Inoue, T., Endo, T., & Carvalho Júnior, E. V. (2025). Influence of treatment modalities on survival and progression free survival in primary spinal cord glioblastoma: a systematic review and individual participant data meta-analysis. European Spine Journal. https://doi.org/10.1007/s00586-025-09516-2
Vancouver
Guerra PLN, Silva ICS, Lima D, Souza MR, Inoue T, Endo T, et al. Influence of treatment modalities on survival and progression free survival in primary spinal cord glioblastoma: a systematic review and individual participant data meta-analysis. European Spine Journal. 2025. doi:10.1007/s00586-025-09516-2
BibTeX
@article{Guerra2025,
author = {Guerra, Pedro Lucas Negromonte and Silva, Inaê Carolline Silveira and Lima, Deoclides and Souza, Mateus Rodrigues and Inoue, Tomoo and Endo, Toshiki and Carvalho Júnior, Eduardo Vieira},
title = {Influence of treatment modalities on survival and progression free survival in primary spinal cord glioblastoma: a systematic review and individual participant data meta-analysis},
journal = {European Spine Journal},
year = {2025},
doi = {10.1007/s00586-025-09516-2}
}
EUVIMED